Durable remission of refractory and advanced stage mycosis fungoides/sezary syndrome utilizing an "outpatient" alemtuzumab, fludarabine-based reduced intensity allogeneic hematopoietic cell transplantation
Bone Marrow Transplant
.
2024 Dec;59(12):1777-1779.
doi: 10.1038/s41409-024-02380-6.
Epub 2024 Sep 9.
Authors
Phuong Vo
1
2
3
,
Ramaprasad Srinivasan
4
,
Enkhtsetseg Purev
1
,
Emily McDuffee
1
,
Tatyana Worthy
1
,
Reem Shalabi
1
,
Kristen Wood
1
,
Brian Wells
1
,
Robert Reger
1
,
David Stroncek
5
,
Nancy Geller
6
,
Georg Aue
1
,
Xin Tian
6
,
Richard Childs
7
Affiliations
1
National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
2
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
3
Department of Medicine, University of Washington, Seattle, WA, USA.
4
National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
5
Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, USA.
6
Office of Biostatistics Research, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
7
National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
[email protected]
.
PMID:
39251835
PMCID:
PMC11611726
DOI:
10.1038/s41409-024-02380-6
No abstract available
Publication types
Letter